Loading
A phase 2 trial of Mirvetuximab soravtansine, Bevacizumab, Carboplatin in ovarian cancer, run by AbbVie, now recruiting.
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer is a phase 2 interventional study registered as NCT07059845 by AbbVie, with 400 participants planned, started 2025-11-13 and due to reach its primary completion in 2029-01. Interventions recorded: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Carboplatin, Antibody-drug conjugate (ADC), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/